Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review

Table 1 Summary of efficacy data from randomized, controlled phase III trials of bevacizumab in advanced ovarian cancer

Study (n)	Regimen	ORR (CR + PR), %	Median PFS, months	Median OS, months
Study (n)	Regimen	[p value]	[HR; p value]	[HR; p value]
GOG-0218 [21]	CP + placebo vs. CP + Bev vs. CP + Bev → Bev maintenance	–	10.3 vs. 11.2 vs. 14.1	39.3 vs. 38.7 vs. 39.7
(n = 1,873)			[0.908; 0.16]^a	[1.036; 0.76]^a
(n = 1,873)			[0.717; < 0.001]^b	[0.915; 0.45]^b
ICON7 [22, 23]	CP vs. CP + Bev → Bev maintenance	48 vs. 67	17.4 vs. 19.8	Restricted mean survival time, months
(n = 1,528)	CP vs. CP + Bev → Bev maintenance	[< 0.001]	[0.87; 0.04]	44.6 vs. 44.5
OCEANS [24, 25]	CG + placebo vs. CG + Bev	57.4 vs. 78.5	8.4 vs. 12.4	33.7^c vs. 33.4^c
(n = 484)	CG + placebo vs. CG + Bev	[< 0.0001]	[0.484; < 0.0001]	[0.960; 0.736]
AURELIA [26, 27]	CTx (PLD, P or Top) vs. CTx + Bev	12.6 vs. 30.9	3.4 vs. 6.7	13.3 vs. 16.6
(n = 361)		[0.001]	[0.48; < 0.001]	[0.85; 0.174]

Bev = bevacizumab. C = carboplatin. CR = complete response. CTx = chemotherapy. G = gemcitabine. HR = hazard ratio. ORR = overall response rate. OS = overall survival. P = paclitaxel. PFS = progression-free survival. PLD = pegylated liposomal doxorubicin. PR = partial response. Top = topotecan.
^aCP + Bev vs. CP + placebo.
^bCP + Bev → Bev vs. CP + placebo.
^cInterim data.

ISSN: 1757-2215